Belpointe Asset Management’s Q32 Bio QTTB Stock Holding History

Belpointe Asset Management’s Portfolio QTTB Stock Details QTTB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-133	Closed	-$3.02K	–	3868
2022 Q4	$3.02K	Buy	+133	New	+$3.53K	﹤0.01%	3115

Other funds holding QTTB

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Belpointe Asset Management's QTTB Position: Q1 2023 in Review

Belpointe Asset Management sold out of Q32 Bio (QTTB) in Q1 2023, closing a stake of 133 shares — an estimated $3.02K sold.

Belpointe Asset Management first reported a position in QTTB in Q4 2022 and held it in 1 quarter. The position peaked at $3.02K in Q4 2022. 62 funds tracked by Wall St. Rank hold QTTB as of Q1 2023.

Belpointe Asset Management reported no remaining Q32 Bio position as of Q1 2023 after selling out during the quarter.
Belpointe Asset Management sold 133 Q32 Bio shares in Q1 2023, an estimated $3.02K.
Belpointe Asset Management first reported a position in Q32 Bio in Q4 2022 and held it in 1 quarter.
Belpointe Asset Management's Q32 Bio position peaked at $3.02K in Q4 2022.
62 funds tracked by Wall St. Rank held Q32 Bio as of Q1 2023.

Based on Belpointe Asset Management's 13F filing for Q1 2023, filed 15 May 2023.